HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (3- furylmethyl)eicosa- 5,8,11,14- tetraenamide

an endocannabinoid transporter inhibitor; structure in first source

Also Known As:

N-(3-furylmethyl)ETEA; UCM707

Networked: 6 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hasanein, Parisa: 2 articles (11/2009 - 10/2008)
2.	Fernández-Ruiz, Javier: 2 articles (10/2006 - 01/2006)
3.	Fowler, Christopher J: 2 articles (10/2006 - 05/2004)
4.	Ortega-Gutiérrez, Silvia: 2 articles (01/2006 - 11/2005)
5.	Soltani, Nepton: 1 article (11/2009)
6.	Javanmardi, Kazem: 1 article (10/2008)
7.	De Lago, Eva: 1 article (10/2006)
8.	Gustafsson, Sofia B: 1 article (10/2006)
9.	Jacobsson, Stig O P: 1 article (10/2006)
10.	Nilsson, Jonas: 1 article (10/2006)

Related Diseases

1.	Hyperalgesia 11/01/2009 - "4. The results of the present study indicate that systemic administration of UCM707 and AM404 is effective in ameliorating chemical hyperalgesia in STZ-diabetic rats. " 11/01/2009 - "At 10 and 50 mg/kg, both UCM707 and AM404 reversed chemical hyperalgesia in diabetic rats. " 11/01/2009 - "In the present study, we investigated the efficacy of the systemic administration of the endocannabinoid transport inhibitors UCM707 and AM404 (1, 10 and 50 mg/kg, i.p.) on hyperalgesia during the formalin test in streptozocin (STZ)-induced diabetic rats. "
2.	Glioma (Gliomas) 10/01/2006 - "It is concluded that AM404, VDM11, UCM707 and OMDM2 produce a rapid loss of C6 glioma cell viability over the same concentration range as is required for the inhibition of AEA uptake in vitro, albeit with a longer latency. " 10/01/2006 - "In this study, the effects of four commonly used acyl-based uptake inhibitors [N-(4-hydroxyphenyl)arachidonylamide (AM404), N-(4-hydroxy-2-methylphenyl) arachidonoyl amide (VDM11), (5Z,8Z,11Z,14Z)-N-(3-furanylmethyl)-5,8,11,14-eicosatetraenamide (UCM707) and (9Z)-N-[1-((R)-4-hydroxybenzyl)-2-hydroxyethyl]-9-octadecen-amide (OMDM2)] and the related compound arvanil on C6 glioma cell viability were investigated. " 05/10/2004 - "Recently, three compounds, UCM707 [N-(Fur-3-ylmethyl)arachidonamide], OMDM-1 and OMDM-2 [the 1'-(S)- and 1'-(R)-enantiomers of the 1'-4-hydroxybenzoyl analogue of oleoylethanolamide], selective for the uptake process, have been described and we have used these compounds, together with AM404 [(N-(4-hydroxyphenyl) arachidonoyl amide)] and VDM11 [(5Z,8Z,11Z,14Z)-N-(4-Hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide]), with the initial aim of determining which mechanism of uptake predominates in C6 glioma and RBL-2H3 cells. "
3.	Parkinson Disease (Parkinson's Disease) 01/01/2006 - "In the present study, we examined whether the treatment with UCM707 produced beneficial effects, as other cannabinoid-related compounds have already shown, to alleviate motor deterioration or to delay/arrest neurodegeneration, in several models of neurological diseases such as Huntington's disease (HD), Parkinson's disease (PD) and multiple sclerosis (MS). "
4.	Multiple Sclerosis 01/01/2006 - "UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders." 01/01/2006 - "In the present study, we examined whether the treatment with UCM707 produced beneficial effects, as other cannabinoid-related compounds have already shown, to alleviate motor deterioration or to delay/arrest neurodegeneration, in several models of neurological diseases such as Huntington's disease (HD), Parkinson's disease (PD) and multiple sclerosis (MS). "
5.	Huntington Disease (Huntington's Disease) 01/01/2006 - "UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders." 01/01/2006 - "In the present study, we examined whether the treatment with UCM707 produced beneficial effects, as other cannabinoid-related compounds have already shown, to alleviate motor deterioration or to delay/arrest neurodegeneration, in several models of neurological diseases such as Huntington's disease (HD), Parkinson's disease (PD) and multiple sclerosis (MS). "

Related Drugs and Biologics

1.	N-(4-hydroxyphenyl)arachidonylamide (AM404)
2.	Endocannabinoids
3.	Streptozocin (Streptozotocin)
4.	Formaldehyde (Formol)
5.	Amides
6.	N- (2- methyl- 3- hydroxyphenyl)- 5,8,11,14- eicosatetraenamide
7.	Cannabinoids
8.	arvanil
9.	anandamide (arachidonylethanolamide)
10.	Interleukin-1beta (Interleukin 1 beta)